FibroBiologics, Inc.
For the period ended Jun 30, 2026. Filed Jul 31, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 31, 2026
FBLG$0.96-2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporation By Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | Form | SECFile No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-41934 | 3.1 | August 28, 2024 |
| 3.2 | Amendment to Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 001-41934 | 3.1 | June 13, 2025 |
| 3.3 | Amendment to Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-41934 | 3.1 | April 3, 2026 |
| 3.4 | Second Amended and Restated Bylaws of the Registrant | 8-K | 001-41934 | 3.1 | April 17, 2026 |
| 4.1 | Form of Common Stock Purchase Warrant issued April 2, 2026 | 8-K | 001-41934 | 4.1 | April 2, 2026 |
| 4.2 | Form of Pre-Funded Common Stock Purchase Warrant issued April 2, 2026 | 8-K | 001-41934 | 4.2 | April 2, 2026 |
| 4.3 | Form of Placement Agent Warrant issued April 2, 2026 | 8-K | 001-41934 | 4.3 | April 2, 2026 |
| 4.4 | Form of Pre-Funded Warrant issued June 29, 2026 | 8-K | 001-41934 | 4.1 | June 29, 2026 |
| 4.5 | Form of warrants issued June 29, 2026 | 8-K | 001-41934 | 4.2 | June 29, 2026 |
| 4.6 | Form of Placement Agent Warrant issued June 29, 2026 | 8-K | 001-41934 | 4.3 | June 29, 2026 |
| 10.1 | Form of Securities Purchase Agreement, dated March 31, 2026, between FibroBiologics, Inc. and the purchasers named therein | 8-K | 001-41934 | 10.1 | April 2, 2026 |
| 10.2 | Form of Securities Purchase Agreement, dated June 25, 2026, between FibroBiologics, Inc. and the purchaser named therein | 8-K | 001-41934 | 10.1 | June 29, 2026 |
| 10.3 | Form of Registration Rights Agreement, dated June 25, 2026, between FibroBiologics, Inc. and the purchaser named therein | 8-K | 001-41934 | 10.2 | June 29, 2026 |
| 10.4+ | FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan | 8-K | 001-41934 | 10.1 | June 23, 2026 |
| 10.5+ | Form of Stock Option Agreement | 8-K | 001-41934 | 10.2 | June 23, 2026 |
| 10.6 | At The Market Offering Agreement dated May 1, 2026 between the Company and H.C. Wainwright & Co., LLC | 8-K | 001-41934 | 1.1 | May 1, 2026 |
| 10.7 | Sublease Buyout Agreement, dated April 3, 2026, between FibroBiologics, Inc. and United Fire & Casualty Co. (doing business as United Fire Group) | ||||
| 31.1 | Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. | ||||
| 31.2 | Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended. | ||||
| 32.1 | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* | ||||
| 101.INS | Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Schema Document. |
| 101.CAL | Inline XBRL Taxonomy Calculation Linkbase Document. |
| 101.DEF | Inline XBRL Taxonomy Definition Linkbase Document. |
| 101.LAB | Inline XBRL Taxonomy Label Linkbase Document. |
| 101.PRE | Inline XBRL Taxonomy Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, and 101.PRE). |
- Indicates management contract or compensatory plan.
- The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.